Seedlabs

Objective Progress Battery for Digital ADHD Therapy

A 10-minute digital test that measures actual changes in attention and memory for ADHD therapy.

A standardized 10-minute objective outcome battery — CPT reaction time plus short working-memory and inhibition tasks — embedded inside digital ADHD therapies, generating monthly before/after change reports for parents, clinicians, and payers at moments when symptom rating scales show little movement.

MedicineAttention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderDigital therapeutics for pediatric behavioral health — in-treatment outcome measurement and reporting

Concept

A standardized, ~10-minute objective outcome battery that digital ADHD therapy providers embed in their product. The child completes it at baseline and monthly: a continuous performance test (reaction time), a short working-memory task, and a short inhibition task — the same task types the clinical trials rely on. The module generates a one-page before/after change report for the parent and treating clinician, showing whether the therapy is producing measurable cognitive change in this particular child. The wedge is sensitive, standardized progress measurement inside the therapy itself: it addresses the field's stated lack of consensus on outcome measures and gives digital therapy makers the objective progress evidence that reimbursement and family engagement depend on.

Why now

In paper [1]'s meta-analysis, objective computerized outcomes detected clearly larger effects of digital therapy (executive function 0.71, working memory 0.48, CPT reaction time -0.40) than symptom rating scales did (inattention -0.20; hyperactivity/impulsivity -0.07, not significant) — and the authors explicitly flag the lack of consensus on outcome measures as a core limitation. Exercise trials in the same population likewise standardize on neurocognitive tasks rather than ratings [0]. That asymmetry means an embedded objective battery is both the more sensitive signal of change and the missing standardization layer: parents and payers currently see little movement on rating scales even when measurable cognitive gains are occurring, and digital therapeutics are already deployed in the field [1], so the module can ride existing products rather than waiting for new ones.

Written by GLM · 9 Oct 2026

AI assessment

Backed by 2 papers92

A high-utility B2B measurement tool that solves a specific pain point for digital therapeutic providers by replacing subjective rating scales with objective, evidence-backed cognitive markers.

Evidence strength
5/5
The idea is directly derived from the full-text results of two meta-analyses showing that objective neurocognitive tasks (CPT, EF, working memory) yield significantly stronger effect sizes than symptom rating scales.
Market pull
4/5
Digital therapeutic companies and payers have a strong incentive for objective 'proof of efficacy' to justify reimbursement and reduce patient churn.
Novelty & moat
4/5
While other ideas focus on treatment or diagnosis, this is a distinct 'measurement layer' that fills the gap between clinical trial evidence and real-world monitoring.
Feasibility
5/5
The tasks (CPT, working memory, inhibition) are well-standardized and computationally simple to implement as a module.
Wedge clarity
5/5
The wedge is extremely sharp: a 10-minute objective battery embedded in existing ADHD apps to provide monthly progress reports.
Simplicity / focus
5/5
The product is a single, focused tool with one clear purpose: objective outcome measurement.

Scored by Gemma 4 · 9 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Akili Interactivecompany

    Needs objective in-treatment outcomes to demonstrate value to payers for EndeavorRx; a standardized embedded battery supplies that progress evidence at scale.

  • Brightlinecompany

    Pediatric behavioral-health telehealth; objective monthly change reports strengthen family engagement and give its clinicians visible progress data during digital therapy.

  • MHS (Multi-Health Systems)company

    Publishes the Conners rating scales and CPT used in ADHD assessment; a standardized digital progress battery is a natural adjacent product and distribution channel for its existing clinician base.

  • CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder)organization

    Families it supports get visible, objective evidence of whether a digital therapy is working for their child, instead of relying on subjective impressions that the meta-analysis shows often miss real change.

  • CVS Health (Aetna)company

    As a payer covering digital ADHD therapy, objective progress reports provide a defensible, standardized basis for continued-coverage decisions.

Research it builds on

  1. The impact of exercise interventions concerning executive functions of children and adolescents with attention-deficit/hyperactive disorder: a systematic review and meta-analysis
    Xiao Liang, Ru Li, Stephen Heung‐Sang Wong et al. · 2021 · 151 citations
    All ideas from this paper →
  2. Meta-analysis of the efficacy of digital therapies in children with attention-deficit hyperactivity disorder
    Fan He, Yan‐Jie Qi, Yuanyue Zhou et al. · 2023 · 44 citations
    All ideas from this paper →
Leave feedback
feasibility